Our vision is to transform the traditional drug discovery by combining advanced neuroscience tools, AI/ML engines and human-derived, proprietary data to uncover novel targets and develop more translatable drug candidates, and at faster speed and less cost.
Our lead clinical asset, backed by promising proof-of-concept efficacy data and exciting pk profile, is undergoing pre-clinical optimization for ALS and FTD, with IND filing planned for 2023.